

- absence of nuclear localization of XPA, AKAP12, and ATR-pS435 in unirradiated cells transfected with wild-type AKAP12 when the original images showed positive signal
- confocal microscopic images of melanocytes in Figure 6H of *Nucleic Acids Res.* 2016 by inserting blank image panels to falsely represent the absence of nuclear localization of XPA, AKAP12, and ATR-pS435 in unirradiated cells transfected with mutant AKAP12 when the original images showed positive signal
 - confocal microscopic images of melanocytes in Figure 5A of *Sci. Rep.* 2017, by inserting blank image panels in the top row, panels 1 and 4, to falsely represent negative control experiments, and the quantification reported in Figure 5B that was derived from falsified and/or fabricated images in Figure 5A
 - confocal microscopic images of melanocytes in Figure 1A, top row, panels 1, 3, 5, and 7, of *JBC* 2018, by inserting blank image panels to represent negative control experiments, and the quantification in Figure 1B that was derived from falsified and/or fabricated images in Figure 1A
 - confocal microscopic images of melanocytes in Figure 2B of *JBC* 2018 by using two different cells from the same source image to falsely represent different experimental results: a cell for control conditions (top row, panel 1) and another cell to represent the outcome of the treatment conditions (top row, panel 8), as well as the quantification reported in Figure 2C that was derived from falsified and/or fabricated images in Figure 2B
 - confocal microscopic images of melanocytes in Figure 3D of *JBC* 2018 by using two different cell images from the same source image to falsely represent different experimental results in: XPA-K215Q transfected cells without forskolin (column 3, rows 1 and 2 of lower right set of panels) and XPA-K215Q transfected cells with forskolin (column 4, rows 1 and 2 of lower right set of panels), and the quantification reported in Figure 3D that was derived from falsified and/or fabricated images in Figure 3D
 - confocal microscopic images of melanocytes in *JBC* 2018 Figure 3D, column 1, rows 1 and 2, of “XPA-WT” set of panels, and in *JBC* 2018 Figure 3D, column 1, rows 1 and 2, of “XPA-K63Q” set of panels, by using the same image field to represent UV untreated cells “XPA-WT” and “XPA-K63Q” mutant, and the quantification reported in Figure 3D

that was derived from falsified and/or fabricated images in Figure 3D

- confocal microscopic images of melanocytes in Figure 2D (images in column 1, rows 1 and 3) of *Mol. Cell* 2014 by reusing, manipulating, and relabeling an image to falsely represent the absence of [6-4]-PP in both vehicle-treated cells and forskolin-treated cells in negative control experiments
- confocal microscopic images of melanocytes in Figure 7C of *Mol. Cell* 2014 (and in Figure 2F of R01 CA207312-01, Figure 5A of R01 CA131075-06, and Figure 3B of R01 CA131075-06A1), by inserting blank image panels to falsely represent forskolin-treated cells and untreated cells without UV exposure, and the quantification reported in Figure 7C and Figure 5A of R01 CA131075-06 that was derived from falsified and/or fabricated images in Figure 7C
- confocal microscopic images of melanocytes in Figure 4E of R01 CA131075-06A1 and Figure 4C of R01 CA207312-01 by using cell images from the same source micrograph to falsely represent cAMP-augmented interaction between pS435-ATR and AKAP12

The following administrative actions have been implemented:

(1) For a period of four (4) years, beginning on July 18, 2022, Respondent is debarred from participating in “covered transactions” as defined in 42 CFR 180.200 and procurement transactions covered under the Federal Acquisition Regulation (48 CFR chapter 1).

(2) Respondent is prohibited from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of four (4) years, beginning on July 18, 2022.

(3) In accordance with 42 CFR 93.407(a)(1) and 93.411(b), HHS will send to the journal *Molecular Cell* a notice of ORI’s findings and the need for retraction of *Mol. Cell* 2014 Jun 19;54(6):999–1011; doi: 10.1016/j.molcel.2014.05.030.

Dated: August 8, 2022.

Wanda K. Jones,

*Acting Director, Office of Research Integrity,
Office of the Assistant Secretary for Health.*

[FR Doc. 2022–17264 Filed 8–10–22; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Cell Biology Integrated Review Group; Cellular Signaling and Regulatory Systems Study Section.

Date: September 26–27, 2022.

Time: 10:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: David Balasundaram, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5189, MSC 7840, Bethesda, MD 20892, 301–435–1022, balasundaramd@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; NIH Research Enhancement Award (R15) in Oncological Sciences.

Date: September 28, 2022.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Svetlana Kotliarova, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6214, Bethesda, MD 20892, 301–594–7945, kotliars@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: August 8, 2022.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–17301 Filed 8–10–22; 8:45 am]

BILLING CODE 4140–01–P